Sign In
Buy SPRB
$42.83
-0.540 (-1.25%)
At Close: Jul 31, 2026
Spruce Biosciences to Participate in May Investor Conferences
04:05pm, Wednesday, 01'st May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocri
LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
04:05pm, Tuesday, 30'th Apr 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocri
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
04:05pm, Monday, 22'nd Apr 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocri
LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
07:15pm, Thursday, 04'th Apr 2024
NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such investors are advised
LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / April 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
05:36pm, Wednesday, 27'th Mar 2024
NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such investors are advise
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 27'th Mar 2024
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
